Praxis Labs is a biotechnology company that is focused on developing therapies for patients with cancer. The company's lead product candidate is PRAX-114, which is a small molecule inhibitor of the DNA damage response pathway. PRAX-114 is currently in Phase 1 clinical trials for the treatment of solid tumors. Praxis Labs was founded in 2017 and is headquartered in San Francisco, California.